Tested Applications
| Positive WB detected in | L02 cells, HL-60 cells, HepG2 cells, Jurkat cells |
| Positive IHC detected in | human liver tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | HeLa cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
15742-1-AP targets TRIM14 in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag8158 Product name: Recombinant human TRIM14 protein Source: e coli.-derived, PET28a Tag: 6*His Domain: 1-346 aa of BC006333 Sequence: MAGAATGSRTPGRSELVEGCGWRCPEHGDRVAELFCRRCRRCVCALCPVLGAHRGHPVGLALEAAVHVQKLSQECLKQLAIKKQQHIDNITQIEDATEKLKANAESSKTWLKGKFTELRLLLDEEEALAKKFIDKNTQLTLQVYREQADSCREQLDIMNDLSNRVWSISQEPDPVQRLQAYTATEQEMQQQMSLGELCHPVPLSFEPVKSFFKGLVEAVESTLQTPLDIRLKESINCQLSDPSSTKPGTLLKTSPSPERSLLLKYARTPTLDPDTMHARLRLSADRLTVRCGLLGSLGPVPVLRFDALWQVLARDCFATGRHYWEVDVQEAGAGWWVGAAYASLRR Predict reactive species |
| Full Name | tripartite motif-containing 14 |
| Calculated Molecular Weight | 442 aa, 50 kDa |
| Observed Molecular Weight | 50 kDa |
| GenBank Accession Number | BC006333 |
| Gene Symbol | TRIM14 |
| Gene ID (NCBI) | 9830 |
| RRID | AB_2209324 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q14142 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
Tripartite motif-containing 14(TRIM14) belongs to the TRIM protein family that contains 3 zinc-binding domains, a RING, a B-box type1 and a B-box type2 and plays key roles in cellular proliferation, differentiation, development, transformation, and immune response mechanisms . TRIM4 inhibits the transcriptional activity of SPI1 in a dose-dependent manner. It may participate in the early stages of differentiation of embryonic stem cells, leading to the formation of embryoid bodies.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for TRIM14 antibody 15742-1-AP | Download protocol |
| IHC protocol for TRIM14 antibody 15742-1-AP | Download protocol |
| WB protocol for TRIM14 antibody 15742-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The TRIM14 antibody (Cat# 15742-1-AP) has 18 total citations published across 15 journals, including Cell Reports, Journal of Translational Medicine, Molecular Medicine, Scientific Reports, Life Sciences, International Journal of Molecular Sciences, ESMO Open, and eLife. The research spans oncology (NSCLC, colorectal, glioblastoma, hepatocellular, gastric, endometrial, and osteosarcoma cancers), immunology, stem cell/exosome biology, diabetic nephropathy, cardiovascular disease, and developmental biology. Applications include WB, IHC, IF, IP, and CoIP.
| Species | Application | Title |
|---|---|---|
ESMO Open Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10. | ||
J Transl Med LncRNA GAS6-AS1 facilitates tumorigenesis and metastasis of colorectal cancer by regulating TRIM14 through miR-370-3p/miR-1296-5p and FUS
| ||
Mol Med Human mesenchymal stem cells derived exosomes inhibit the growth of acute myeloid leukemia cells via regulating miR-23b-5p/TRIM14 pathway.
| ||
Cell Rep Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis | ||
Cell Rep Mechanotransduction in response to ECM stiffening impairs cGAS immune signaling in tumor cells
| ||
Life Sci Piperlongumine-inhibited TRIM14 signaling sensitizes glioblastoma cells to temozolomide treatment
|
